LENZ Therapeutics, Inc. (LENZ)
(Delayed Data from NSDQ)
$21.86 USD
+1.21 (5.86%)
Updated Sep 13, 2024 03:59 PM ET
After-Market: $21.83 -0.03 (-0.14%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LENZ 21.86 +1.21(5.86%)
Will LENZ be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LENZ based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for LENZ
RTW Biotech half-year net asset value rises amid "challenging markets"
Lenz Therapeutics files to sell 1.58M shares of common stock for holders
LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks
LENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024